8-K: Elanco Animal Health Q1 2026 Results: Outlook Raised

Elanco Animal Health reported strong first quarter 2026 results, with revenue up 15% year-over-year, and raised its full-year financial guidance.

Summary

• Elanco Animal Health reported first quarter 2026 revenue of $1,371 million, a 15% increase year-over-year, or 10% on an organic constant currency basis.
• Reported net income was $57 million, or $0.11 per diluted share, while adjusted net income was $204 million, or $0.40 per diluted share, an 8% increase.
• Adjusted EBITDA reached $334 million, a 21% increase year-over-year, with an adjusted EBITDA margin of 24.5%.
• The company raised its full-year 2026 revenue guidance to $5,010 million - $5,085 million (5%-7% organic constant currency growth), and its Adjusted EBITDA guidance to $975 million - $1,005 million.
• Full-year Adjusted EPS guidance was also raised to $1.03 - $1.09, and the year-end net leverage ratio target improved to 3.0x - 3.2x Adjusted EBITDA.
• Key product highlights include Zenrelia reaching blockbuster status and Credelio Quattro accelerating market share gains.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a positive report, with strong Q1 results and a raised full-year outlook indicating robust business momentum and effective execution of the company's strategy.

Positives

• Revenue increased by 15% year-over-year to $1,371 million in Q1 2026.
• Organic constant currency revenue growth was 10% in Q1 2026.
• Adjusted EBITDA increased by 21% to $334 million in Q1 2026.
• Adjusted EBITDA margin improved to 24.5% from 23.1% in Q1 2025.
• Full-year revenue guidance was raised to $5,010 million - $5,085 million.
• Full-year Adjusted EBITDA guidance was raised to $975 million - $1,005 million.
• Full-year Adjusted EPS guidance was raised to $1.03 - $1.09.
• Year-end net leverage ratio target improved to 3.0x - 3.2x Adjusted EBITDA.

Negatives

• Reported net income decreased by 15% to $57 million in Q1 2026 compared to $67 million in Q1 2025.
• Reported EPS decreased to $0.11 in Q1 2026 from $0.13 in Q1 2025.
• Adjusted gross margin percentage decreased by 40 basis points to 57.0% in Q1 2026 compared to Q1 2025, primarily due to product mix and higher inventory costs.
• Total operating expenses increased by 10% in Q1 2026 compared to Q1 2025.
• Net interest expense increased by $17 million in Q1 2026 compared to Q1 2025, partly due to imputed interest on the liability for sale of future revenue.

Risks

• Operating in a highly competitive industry.
• The success of research and development, regulatory approval, and licensing efforts.
• Impact of disruptive innovations and advances in veterinary medical practices and technologies.
• Competition from generic products.
• Changes in regulatory restrictions on the use of antibiotics in farm animals.
• An outbreak of infectious disease carried by farm animals.
• Consolidation of customers and distributors.
• Dependence on the success of top products.

Future Outlook

The company raised its full-year 2026 guidance, now expecting revenue between $5,010 million and $5,085 million (5%-7% organic constant currency growth), Adjusted EBITDA between $975 million and $1,005 million, and Adjusted EPS between $1.03 and $1.09. The year-end net leverage ratio target was improved to 3.0x to 3.2x Adjusted EBITDA. For the second quarter of 2026, revenue is projected to be between $1,300 million and $1,325 million.

Management Comments

• "Elanco's strong first quarter results demonstrate the significant momentum of our innovation-led strategy," said Jeff Simmons, President and CEO of Elanco.
• "Organic constant currency revenue growth of 10% reflects outperformance across our diverse portfolio, including Zenrelia reaching trailing 4-quarter blockbuster status, and Credelio Quattro achieving accelerating market share gains."
• "We are improving our full year guidance across all key metrics, as our consistent execution is creating more ways for Elanco to win in this durable, attractive animal health industry."
• "This outperformance, driven by both volume and price, gives us the confidence to raise our full-year guidance for revenue, adjusted EBITDA, and adjusted EPS, while continuing to take a prudent, balanced approach in a dynamic macro environment," said Bob VanHimbergen, Executive Vice President and CFO of Elanco Animal Health.

Industry Context

StockSavvy.ai notes that Elanco's performance, particularly the strong organic growth and raised guidance, aligns with a generally robust animal health sector driven by innovation and increasing demand for pet and farm animal care. The company's focus on new product launches like Zenrelia and Credelio Quattro highlights a key industry trend of investing in R&D to capture market share.

Stakeholder Impact

• Shareholders: Positively impacted by raised full-year guidance and improved financial outlook.
• Customers (Farmers, Pet Owners, Veterinarians): Benefit from innovative products and treatments.
• Employees: Potential for increased investment in strategic initiatives and product launches.
• Suppliers: May see increased demand for raw materials due to higher production volumes.

Next Steps

• Commercialization of Befrena in the U.S. expected in Q2 2026.
• Continued focus on innovation-led strategy and execution of Elanco Ascend initiative.
• Webcast and conference call held on May 6, 2026, to discuss results and guidance.

Key Dates

Recommendation

While the results are strong and guidance has been raised, the company operates in a competitive market with inherent risks. The current valuation and execution of future product launches will be key. A 'hold' recommendation allows for further observation of sustained performance and market dynamics.

Keywords

Animal Health, Elanco, Q1 2026 Results, Revenue Growth, EBITDA, EPS Guidance, Innovation, Pet Health